744256-69-7

Basic information

• Product Name: Thieno[3,2-c]pyridine-5(4H)-acetic acid, a-(2-chlorophenyl)-6,7-dihydro-, Methyl ester, (aS)-, benzenesulfonate
• Synonyms: Thieno[3,2-c]pyridine-5(4H)-acetic acid, a-(2-chlorophenyl)-6,7-dihydro-, Methyl ester, (aS)-, benzenesulfonate;Clopidogrel benzenesulfonate;CLOPIDOGREL BESILATE
• CAS NO: 744256-69-7
• Molecular Formula: C21H20ClNO5S2
• Molecular Weight: 465.9702
• EINECS: 283-403-6
• Mol File: 744256-69-7.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Thieno[3,2-c]pyridine-5(4H)-acetic acid, a-(2-chlorophenyl)-6,7-dihydro-, Methyl ester, (aS)-, benzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: Thieno[3,2-c]pyridine-5(4H)-acetic acid, a-(2-chlorophenyl)-6,7-dihydro-, Methyl ester, (aS)-, benzenesulfonate(744256-69-7)
• EPA Substance Registry System: Thieno[3,2-c]pyridine-5(4H)-acetic acid, a-(2-chlorophenyl)-6,7-dihydro-, Methyl ester, (aS)-, benzenesulfonate(744256-69-7)

Safety Data

• Hazardous Substances Data: 744256-69-7(Hazardous Substances Data)

Usage

General Description

Thieno[3,2-c]pyridine-5(4H)-acetic acid, a-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (aS)-, benzenesulfonate is a chemical compound with the molecular formula C19H17ClNO3S. It is a methyl ester derivative of thieno[3,2-c]pyridine-5(4H)-acetic acid, a compound with potential anti-inflammatory and analgesic properties. The (aS)- stereoisomer of the compound has been found to exhibit inhibitory activity against cyclooxygenase-2, an enzyme that plays a key role in the inflammatory process. These properties make it a potential candidate for the development of new drugs for the treatment of inflammatory conditions and pain management. The benzenesulfonate salt form of this compound is often used for research and experimental purposes in the pharmaceutical industry.

Upstream product

• 90055-48-4 clopidogrel 
• 98-11-3 benzenesulfonic acid 
• 113665-84-2 (S)-(+)-clopidogrel 
• 28783-41-7 6,7-dihydro-4H-thieno[3,2-c]pyridine hydrochloride 
• 120202-66-6 (S)-(+)-clopidogrel bisulfate 
• 223123-46-4 methyl (R)-2-(2-chlorophenyl)-2-benzenesulfonyloxyacetate 

Relevant articles and documents

Preparation method of high-purity clopidogrel

The invention relates to a preparation method of high-purity clopidogrel (formula I). The preparation method comprises the following steps: firstly, performing reaction on a compound as shown in formula II and a compound as shown in formula III in an acetone solvent under the existence of alkali, filtering reactants to remove insolubles, and adding sulfuric acid into filtrate for separation and crystallization, thus obtaining clopidogrel disulfate with the optical purity of 98 percent or above; neutralizing the clopidogrel disulfate with inorganic alkali in dichloromethane and water, obtaining clopidogrel free alkali, salifying the clopidogrel free alkali and benzenesulfonic acid in an alcohol solvent, then adding an alkane solvent for separation and crystallization, thus obtaining clopidogrel benzene sulfonate (formula V) with the optical purity of 99.9 or above, and applying the clopidogrel benzene sulfonate to a medicine preparation, or neutralizing the clopidogrel disulfate with the inorganic alkali in the dichloromethane and the water, thus obtaining the clopidogrel free alkali with the optical purity of 99.9 percent, and applying the clopidogrel free alkali to preparation of pharmaceutically acceptable salt and a medicine preparation.

HIGHLY PURE SALTS OF CLOPIDOGREL FREE OF GENOTOXIC IMPURITIES

The present invention relates to substantially pure salts of clopidogrel of Formula (I) substantially free from genotoxic impurities. (I) wherein (S) represents a suitable organic or inorganic acid, which forms a salt with clopidogrel having less acidity.

Pharmaceutical formulations comprising clopidogrel

The formation of melt granulates comprising the drug clopidogrel of the following formula or a pharmaceutically acceptable salt thereof markedly reduces degradation of clopidogrel and its salts on storage.